Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

AI Integration in Ophthalmology for Healthcare and Drug Discovery

AI Integration in the Fight Against Age-Related Macular Degeneration

Jan 3 2024

Reviewed by Danielle Ellis, B.Sc.

In a recent interview at ELRIG UK Drug Discovery 2023, Wen Hwa Lee, CEO, and Chief Scientist at Action Against Age-Related Macular Degeneration (AAAMD), sheds light on the integration of AI in ophthalmology to advance healthcare and drug discovery.

Wen Hwa Lee, the CEO of AAAMD, started his career as a molecular biologist and geneticist before delving into structural and computational biology. His expertise led to a focus on big data space and drug discovery. When the AAAMD charity was established, Lee’s unique profile made him the ideal candidate to spearhead the development of innovative approaches and therapies to prevent or slow AMD.

Lee highlighted the challenges in utilizing AI for healthcare, particularly in ophthalmology, citing data fragmentation, standardization, and integration as primary obstacles. To address these challenges, AAAMD prioritizes participant-centric data aggregation and a common data framework. The organization aims to integrate ophthalmic scans with other omics and promote public participation in research programs.

Furthermore, Lee emphasized the existence of gaps in healthcare data for training AI algorithms, noting that healthcare data often focuses on disease rather than health. This leads to deficiencies in predictive and preventive healthcare. AAAMD’s approach includes capturing data related to pre-disease, pre-diagnostic, and pre-hospitalization stages to facilitate early intervention and targeted drug discovery. The organization’s focus on public participation in addition to patient participation underscores their objective to leverage data that extends beyond immediate disease manifestation.

Lee also discussed the significance of collaboration across sectors, emphasizing its pivotal role in improving data availability for AI-driven research in ophthalmology and healthcare at large. AAAMD’s ongoing Foresight project exemplifies their commitment to implementing multi-sector collaborations to enhance data accessibility for AI-driven research.

Image Credit: LALAKA/Shutterstock.com

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *